Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine.

Abstract

An explosion in the incidence of neurodegenerative diseases, particularly Alzheimer's disease (AD), is predicted in coming decades. Hence, the need to devise and assess new treatment strategies has never been more acute. AD, although an irreversible and progressive disorder, is currently treated with palliative, symptomatic therapy: primarily with… (More)

Topics

Cite this paper

@article{Kamal2006KineticsOH, title={Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine.}, author={Mohammad Amjad Kamal and Peter S Klein and Qian-sheng Yu and David Tweedie and Yazhou Li and Harold W. Holloway and Nigel H. Greig}, journal={Journal of Alzheimer's disease : JAD}, year={2006}, volume={10 1}, pages={43-51} }